Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

621 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
DNA methylation marker to estimate ovarian cancer cell fraction.
Ebata T, Yamashita S, Takeshima H, Yoshida H, Kawata Y, Kino N, Yasugi T, Terao Y, Yonemori K, Kato T, Ushijima T. Ebata T, et al. Among authors: terao y. Med Oncol. 2022 Feb 23;39(5):78. doi: 10.1007/s12032-022-01679-y. Med Oncol. 2022. PMID: 35195779
Discrepancies in pathological diagnosis of endometrial stromal sarcoma: a multi-institutional retrospective study from the Japanese clinical oncology group.
Yoshida H, Kikuchi A, Tsuda H, Sakamoto A, Fukunaga M, Kaku T, Yoshida M, Shikama A, Kogata Y, Terao Y, Tanikawa M, Yasuoka T, Chiyoda T, Miyamoto T, Okadome M, Nakamura T, Enomoto T, Konno Y, Yahata H, Hirata Y, Aoki Y, Tokunaga H, Usui H, Yaegashi N. Yoshida H, et al. Among authors: terao y. Hum Pathol. 2022 Jun;124:24-35. doi: 10.1016/j.humpath.2022.03.007. Epub 2022 Mar 24. Hum Pathol. 2022. PMID: 35339567
DNA methylation of the immediate upstream region of BRCA1 major transcription start sites is an independent favorable prognostic factor in patients with high-grade serous ovarian cancer.
Ebata T, Yamashita S, Takeshima H, Yoshida H, Kawata Y, Kino N, Yasugi T, Terao Y, Yonemori K, Kato T, Ushijima T. Ebata T, et al. Among authors: terao y. Gynecol Oncol. 2022 Dec;167(3):513-518. doi: 10.1016/j.ygyno.2022.10.008. Epub 2022 Oct 15. Gynecol Oncol. 2022. PMID: 36253303
High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway.
Yoshihara K, Tsunoda T, Shigemizu D, Fujiwara H, Hatae M, Fujiwara H, Masuzaki H, Katabuchi H, Kawakami Y, Okamoto A, Nogawa T, Matsumura N, Udagawa Y, Saito T, Itamochi H, Takano M, Miyagi E, Sudo T, Ushijima K, Iwase H, Seki H, Terao Y, Enomoto T, Mikami M, Akazawa K, Tsuda H, Moriya T, Tajima A, Inoue I, Tanaka K; Japanese Serous Ovarian Cancer Study Group. Yoshihara K, et al. Among authors: terao y. Clin Cancer Res. 2012 Mar 1;18(5):1374-85. doi: 10.1158/1078-0432.CCR-11-2725. Epub 2012 Jan 12. Clin Cancer Res. 2012. PMID: 22241791
Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma.
Itamochi H, Oishi T, Oumi N, Takeuchi S, Yoshihara K, Mikami M, Yaegashi N, Terao Y, Takehara K, Ushijima K, Watari H, Aoki D, Kimura T, Nakamura T, Yokoyama Y, Kigawa J, Sugiyama T. Itamochi H, et al. Among authors: terao y. Br J Cancer. 2017 Aug 22;117(5):717-724. doi: 10.1038/bjc.2017.228. Epub 2017 Jul 20. Br J Cancer. 2017. PMID: 28728166 Free PMC article.
Pathology-oriented treatment strategy of malignant ovarian tumor in pregnant women: analysis of 41 cases in Japan.
Morikawa A, Ueda K, Takahashi K, Fukunaga M, Iwashita M, Kobayashi Y, Takechi K, Umezawa S, Terauchi F, Kiguchi K, Aoki D, Nomura H, Yoshikawa H, Satoh T, Jobo T, Fujiwara H, Takei Y, Kamoi S, Terao Y, Isonishi S. Morikawa A, et al. Among authors: terao y. Int J Clin Oncol. 2014 Dec;19(6):1074-9. doi: 10.1007/s10147-014-0669-3. Epub 2014 Feb 18. Int J Clin Oncol. 2014. PMID: 24534911
621 results